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ABSTRACT 
In India, there are roughly 30 million heart patients and two Lac surgeries are being performed every year. YOSPRALA-a new 
emerging drug approved by USFDA in September 2016 to treat Ischemic stroke, prophylaxis and gastric ulcer prophylaxis. The 
active ingredients present are Aspirin and Omeprazole. Hence an attempt is made to develop a new analytical method for 
Simultaneous estimation of Aspirin and Omeprazole using methanol as solvent The Absorption maxima of Aspirin and Omeprazole 
was at 224nm and 251.8nm respectively. Linearity range for aspirin was 0.5-25µg/ml with regression co-efficient-099 and 
omeprazole was 1-8µg/ml with regression coefficient 0.992. The method was validated for precision and % RSD was less than 1.5% 
for both aspirin and omeprazole. The proposed method was statistically validated for standard deviation, relative standard deviation, 
coefficient of variance and the results were within the limits. Hence the above method was simple, cost effective, robust and   can be 
used for routine analysis in pharmaceutical preparations. 
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YOSPRALA is designed to support both cardio and 
gastro protection for at risk patients through  proprietary 
intell-coat system, which is formulated to sequentially 
deliver immediate release of 
Omeprazole(40mg)followed by a delayed release 
,enteric coated aspirin core either in (81mg) or 325mg 
dose strength.
1
Yosprala is approved by USFDA on 
September 1
4th




An extensive literature survey reveals that there is no 
analytical method yet reported for simultaneous 
estimation of aspirin and omeprazole in combination by 
any analytical techniques. There are methods been 
developed for estimation of aspirin individually
3
, in 
combination with other drugs by UV Spectroscophy in 
tablet dosage form 
4-6
, by RP-HPLC in bulk
7
 and in 
tablet dosage form
8
, by HPTLC in bulk and synthetic 
mixtiure
9. 
Whereas methods been developed for 
estimation of Omeprazole capsules individually10
-11
, 
bioanalysis of omeprazole by LC-MS/MS
12
 in 
combination with other drugs by RP-HPLC in bulk and 
capsule 
13-14
, in tablet dosage dorm
15
 , by NP-HPLC
16
. 
Hence an attempt was made to develop a simple and cost 
effective method for simultaneous estimation of aspirin 
and omeprazole and the proposed methods was validated 
according to ICH guidelines. 
MATERIALS AND METHODS: 
The reference standard of standard Aspirin (99%purity) 
and omeprazole (99%purity) were purchased from 
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yarrow Chem products (Mumbai, INDIA), DMF 
(99.0%potency), Acetone (99.0%potency), Ethanol 
(99%potency), Methanol (99.0% potency) was 
purchased from Finar Chemicals (Ahmadabad, Gujarat, 
INDIA). 
1) Instrument employed: The instrument employed for 
the study was as follows. 
 






2) Solubility studies: The solubility studies performed using various solvents are listed below. 
Table 2: Solubility studies 
Solvent Aspirin Omeprazole 
Distilled water Sparingly soluble Freely soluble 
0.1NNAOH Sparingly soluble Insoluble 
0.1NHCL Sparingly soluble Freely soluble 
DMF Freely soluble Freely soluble 
Acetone Insoluble Sparingly soluble 
Ethanol Freely soluble Freely soluble 
Methanol Freely soluble Freely soluble 
 
3) Mobile phase selection: Sharp peaks were obtained 
for Aspirin and Omeprazole when methanol was used as 
solvent. 
Table 3: Mobile phase selection 
SOLVENT RESULT 
Distilled water Peak not Satisfactory 
Acetone Peak not Satisfactory 
Ethanol Better but not satisfactory 
Methanol Peak Satisfactory 
 
4) Determination of ƛmax: UV Spectrums of Aspirin 
and Omeprazole were scanned throughout UV region 
and the lambda max obtained for aspirin was at 224.7nm 
and for Omeprazole was at 251.2nm. 
 
 
Figure 1: UV-spectrum of Aspirin (224.7nm) 
 
Figure 2: UV-spectrum of Omeprazole (251.2nm) 
5) Preparation of Stock solution 
5.1. Stock solution of Aspirin 
50mg of Aspirin standard was dissolved in 50ml of 
methanol in 50 ml of volumetric flask which gives 
1000µg/ml. 
10ml of above solution is taken and made up to 100ml 
with Methanol in 100ml standard flask which gives 
100µg/ml. 
5.2. Stock solution of Omeprazole 
50mg of Omeprazole standard was dissolved in 50 ml of 
methanol in 50ml standard flask which gives 
1000µg/ml. 
10ml of above solution is taken and made up to with 
Methanol in 100ml standard flask which gives 
100µg/ml. 
Instrument Employed Double beam UV-VISIBLE spectrophotometer 
Make Systronics 
Model no 2203 
Detector Photo Diode Array 
Source of light Sodium Vapour Lamp 
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6) Sample preparation 
 6.1. Sample preparation of Aspirin 0.5ml of above 
Aspirin stock solution is made up to 10ml with methanol 
in 10ml standard flask which gives 5µg/ml. 
6.2. Sample preparation of omeprazole 
0.1ml of above Omeprazole stock solution is made up to 
10ml with methanol in 10ml standard flask which gives 
1µg/ml. 
RESULTS & DISCUSSION: 
1) System suitability parameters: 
The following parameters are system suitability 
parameters for the analytical method developed 
according to ICH guidelines. 








2) Validation of proposed method: 
2.1) Linearity: It is an analytical procedure is its ability (within a given range) to obtain test results which are directly 
proportional to the concentration (amount) of analyte in the sample. 
2.1.1: For Aspirin: 
Table 5: Linerity results of Aspirin 








2.1.2: For Omeprazole: 
Table 6: Linearity results of Omeprazole 
                                                                                         








According to ICH guidelines Acceptance criteria- the regression co-efficient should NLT 0.99  
2.2) Precision: An analytical procedure expresses the closeness of agreement (degree of scatter) between a series of 
measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. 
 
Sr.no Parameters Aspirin Omeprazole 
1 ƛmax 224.7nm 251.2nm 
2 Slope 0.091 0.288 
3 Regression co-efficient(r
2
) 0.99 0.992 
4 LOD(µg/ml) 1.08µg/ml 1.126µg/ml 
5 LOQ(µg/ml) 3.27 µg/ml 3.00µg/ml 
6 Linearity range 0.5-25µg/ml 1-8µg/ml 
7 Regression Equation Y=0.091x+0.194 Y=0.288x+0.128 
S/NO Conc. (µg/ml) Absorbance (nm) 
1 0 0 
2 0.5 0.276 
3  1 0.372 
4 5 0.699 
5 10 1.169 
6 15 1.568 
7 20 1.998 
8 25 2.448 
S/NO Conc. (µg/ml) Absorbance (nm) 
1 0 0 
2 1 0.484 
3 2 0.749 
4 3 0.997 
5 4 1.283 
6 5 1.626 
7 6 1.896 
8 7 2.167 
9 8 2.329 
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Table 7: Precision results of Apirin and Omeprazole 
 
According to ICH guidelines acceptance criteria for precision the %RSD should NMT 2% 
2.3) Statistical validation: The proposed method was statistically validated for the following parameters and was 
within the Acceptance criteria as per ICH guidelines. 
Table 8: Statistical data of method 
S/NO 1 2 
Drug Aspirin Omeprazole 
Conc.(µg/ml) 5 1 
E=A/g per 100ml ax1 ax2 ay1 ay2 
Absorptivity 72.14 15.02 2.08 60.3 
SD 0.228 0.126 0.0632 0.1897 
SE 0.0268 0.0325 0.0438 0.0244 
RSD 0.0031 0.0083 0.0303 0.0031 
%RSD 0.31% 0.83% 0.03% 0.31% 
C.V. 0.316% 0.838% 0.038% 0.315% 
 
2.4) Ruggedness and Robustness: An analytical procedure is a measure of its capacity to remain unaffected by small, 
deliberate variations in method parameters and provides an indication of its reliability during normal usage. 
2.4.1: Ruggedness:  
Table 9: Ruggedness result 
S/No Drug (n=3) Conc. (µg/ml) Instrument Employed 
   Systronics Shimadzu 
   ax1 ax2 ax1 ax2 
1 Aspirin 2.5 36.56 0.746 36.53 0.75 
  SD 0.081 0.047 0.080 0.054 
   ay1 ay2 ay1 ay2 
2 Omeprazole 1 2 60.23 2.01 60.21 
  SD 0.230 0.077 0.054 0.189 
 
2.4.2: Robustness:  
Table 10: Robustness result 
S/NO Drug (n=3) Conc. (µg/ml) Temperature 






   ax1 ax2 ay1 ay2 
1 Aspirin 2.5 36.56 0.746 36.57 0.745 
  SD 0.081 0.047 0.083 0.048 
   ay1 ay2 ay1 ay2 
2 Omeprazole 1 2 60.23 2.1 60.25 
  SD 0.230 0.077 0.231 0.079 
 


























1 5 0.724 0.150 72.4 1.5 1 0.021 0.603 2.1 60.3 
2 5 0.724 0.151 72.4 1.51 1 0.019 0.603 1.9 60.3 
3 5 0.715 0.149 71.5 1.49 1 0.020 0.601 2.0 60.1 
4 5 0.721 0.150 72.1 1.50 1 0.021 0.599 2.1 59.9 
5 5 0.723 0.151 72.3 1.51 1 0.023 0.600 2.3 60.0 
   Mean 72.14 15.02   Mean 2.08 60.12 
   SD 0.228 0.126   SD 0.0632 0.1897 
   %RSD 0.31% 0.83%   %RSD 0.03% 0.31% 
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CONCLUSION: 
An attempt was made to develop an analytical method 
for simultaneous estimation of Aspirin and Omeprazole 
by UV Spectrosopy. The developed method was 
validated for linearity, precision, ruggestness, robustness 
and results were within the limits according to ICH 
guidelines. The proposed method was cost effective, 
simple, Precise and robust. This is the first report on the 
simultaneous estimation of aspirin and omeprazole in 
bulk by UV-spectrophotometric method. The above 
method can be used for routine analysis of Aspirin and 
Omeprazole in bulk and Tablet Dosage Form. 
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